Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis

AIMS: Renin–angiotensin–aldosterone system inhibitors (RAASi) improve outcomes in cardiorenal disease but concerns have been raised over increased risk of incident hospitalization and death from coronavirus disease 2019 (COVID‐19). We investigated the association between use of angiotensin‐convertin...

Descripción completa

Detalles Bibliográficos
Autores principales: Savarese, Gianluigi, Benson, Lina, Sundström, Johan, Lund, Lars H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2020
Materias:
Covid–19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753665/
https://www.ncbi.nlm.nih.gov/pubmed/33222412
http://dx.doi.org/10.1002/ejhf.2060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753665/
https://www.ncbi.nlm.nih.gov/pubmed/33222412
http://dx.doi.org/10.1002/ejhf.2060

Ejemplares similares